• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Exane BNP Paribas initiated coverage on Elanco Animal Health with a new price target

    12/7/23 6:17:43 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    Exane BNP Paribas initiated coverage of Elanco Animal Health with a rating of Outperform and set a new price target of $18.00
    Get the next $ELAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    12/7/2023$18.00Outperform
    Exane BNP Paribas
    4/20/2023$14.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

      GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

      5/28/25 7:25:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco to Participate in the Upcoming Investor Conferences

      GREENFIELD, Ind., May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, May 22, Jeff Simmons, president and CEO, will participate in the BNP Paribas 2nd Annual Animal Health Day at 12:00 p.m. ET. On Thursday, May 29, Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will participate in a fireside chat at Stifel 2025 Jaws & Paws Conference at 8:00 a.m. ET. Live audio webcasts will be available in the "Events and Presentations" sec

      5/16/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      7/8/24 4:32:39 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/13/24 2:08:55 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

      SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

      2/12/24 4:01:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/20/25 5:23:15 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/20/25 5:22:05 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Modi Rajeev A.

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      5/6/25 4:04:57 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Financials

    Live finance-specific insights

    See more
    • Elanco Animal Health Reports First Quarter 2025 Results

      Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

      5/7/25 6:27:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

      GREENFIELD, Ind., April 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2025 financial results on Wednesday, May 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/defau

      4/10/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement

      GREENFIELD, Ind., Feb. 4, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-pr

      2/4/25 8:00:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Elanco Animal Health with a new price target

      UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

      12/9/24 7:40:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Elanco Animal Health with a new price target

      Leerink Partners initiated coverage of Elanco Animal Health with a rating of Market Perform and set a new price target of $14.00

      12/2/24 6:55:44 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously

      9/19/24 7:41:39 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/11/25 5:13:30 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      3/7/25 4:21:21 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

      4 - Elanco Animal Health Inc (0001739104) (Issuer)

      8/26/24 5:05:35 PM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

      GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

      5/28/25 7:25:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Strengthens Board of Directors with Addition of Stacey Ma

      Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

      11/12/24 8:33:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors

      New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora

      4/1/24 6:30:00 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELAN
    SEC Filings

    See more
    • SEC Form SD filed by Elanco Animal Health Incorporated

      SD - Elanco Animal Health Inc (0001739104) (Filer)

      5/30/25 10:00:37 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elanco Animal Health Inc (0001739104) (Filer)

      5/28/25 7:30:32 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Elanco Animal Health Incorporated

      10-Q - Elanco Animal Health Inc (0001739104) (Filer)

      5/7/25 9:05:18 AM ET
      $ELAN
      Biotechnology: Pharmaceutical Preparations
      Health Care